Repository logo
 

EAP45 association with budding HIV-1: Kinetics and domain requirements.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Meng, Bo 
Vallejo Ramirez, Pedro P 
Scherer, Katharina M 
Bruggeman, Ezra 
Kenyon, Julia C 

Abstract

A number of viruses including HIV use the ESCRT system to bud from the infected cell. We have previously confirmed biochemically that ESCRT-II is involved in this process in HIV-1 and have defined the molecular domains that are important for this. Here, using SNAP-tag fluorescent labelling and both fixed and live cell imaging we show that the ESCRT-II component EAP45 colocalises with the HIV protein Gag at the plasma membrane in a temporal and quantitative manner, similar to that previously shown for ALIX and Gag. We show evidence that a proportion of EAP45 may be packaged within virions, and we confirm the importance of the N terminus of EAP45 and specifically the H0 domain in this process. By contrast, the Glue domain of EAP45 is more critical for recruitment during cytokinesis, emphasising that viruses have ways of recruiting cellular components that may be distinct from those used by some cellular processes. This raises the prospect of selective interference with the pathway to inhibit viral function while leaving cellular functions relatively unperturbed.

Description

Keywords

ESCRT, HIV, TIRF, budding, colocalisation, gag, Endosomal Sorting Complexes Required for Transport, HIV Infections, HIV-1, Humans, Kinetics

Journal Title

Traffic

Conference Name

Journal ISSN

1398-9219
1600-0854

Volume Title

Publisher

Wiley

Rights

All rights reserved
Sponsorship
Medical Research Council (MR/N022939/1)
Engineering and Physical Sciences Research Council (EP/H018301/1)
Wellcome Trust (089703/Z/09/Z)
Medical Research Council (MR/K015850/1)
Medical Research Council (MR/K02292X/1)
Engineering and Physical Sciences Research Council (EP/L015889/1)
Wellcome Trust (203249/Z/16/Z)
Research Visit Grant by the Microbiology Society (BM), Gates Cambridge Scholarship (PVR), UK Medical Research Council (MRC) Grant (MR/N0229939/1)(JCK and AMLL), MRC Grants (MR/K015850/1 and MR/K02292X/1)(CFK), UK Engineering and Physical Sciences Research Council, EPSRC Grants (EP/L015889/1 and EP/H018301/1)(CFK), Wellcome Trust Grants (203249/Z/16/Z and 089703/Z/09/Z)(CFK), MedImmune, the RCUK under the Technology Touching Life Initiative, and Infinitus China Ltd (CFK).